Clal Biotechnology Industries Ltd. (CBI)
12 Abba Hillel Silver Street
9 articles about Clal Biotechnology Industries Ltd. (CBI)
Cambridge, Massachusetts-based Neon Therapeutics is launching an initial public offering (IPO) of 6,250,000 shares of common stock at a price offering of $16 per share.
Hyperion Therapeutics Enters Into Completion Of Phase III Clinical Trial, Option And Mutual Release Agreement With Clal Biotechnology Industries And Yeda Research and Development Company Ltd.
Hyperion Therapeutics, Clal Biotechnology Industries Resolve Dispute Over $570 Million Biotech Problem
Clal Biotechnology Industries Release: Andromeda Announces That Further Data Analyses Support Primary Endpoint in Andromeda Biotech's Phase III Clinical Study
Teva Pharmaceutical Industries Limited, Clal Biotechnology Industries Raises Stake in Diabetes Treatment Developer, Andromeda; Teva and Clal to Invest $17.5 Million
Yissum Ltd., Pontifax, and Clal Biotechnology Industries Invest $9 Million in Avraham Pharmaceuticals Ltd. to Pursue a Phase IIb Clinical Trial of Ladostigil, a Novel Drug for Treatment of Alzheimer's Disease
Arte Ventures And Clal Biotechnology Industries Introduce A New Model For Biotech Investment Management